📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-07 10:38
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Promoter Archana Lonkar Allotted 4.95 Lakh Shares via Share Swap; Holding Dilutes to 4.86%
Promoter Archana Kakasaheb Lonkar was allotted 4,95,000 equity shares in iSERA Lifesciences via preferential allotment (share swap) on October 1, 2026. Following this issuance, her absolute holding increased from 7,00,000 shares to 11,95,000 shares. However, due to a massive expansion in total share capital from 84,08,972 shares (Rs 8.41 Cr) to 2,45,91,772 shares (Rs 24.59 Cr), her percentage holding diluted from 8.32% to 4.86%.
Confidence: HIGH
What changedArchana Lonkar's shareholding changed from 7,00,000 shares (8.32%) to 11,95,000 shares (4.86%) post a share swap preferential allotment.
Why it mattersThe company underwent significant equity dilution, expanding its paid-up capital from Rs 8.41 Cr to Rs 24.59 Cr, altering control dynamics and per-share financials.
Shares Acquired: 4,95,000Pre-allotment Holding: 7,00,000 (8.32%)Post-allotment Holding: 11,95,000 (4.86%)Pre-allotment Total Shares: 84,08,972Post-allotment Total Shares: 2,45,91,772
📅 Short termNeutral trading reaction expected as the disclosure confirms an allotment already approved by the board on October 1, 2026.
📈 Long termThe underlying asset acquired through the share swap that led to a ~192% share base expansion will dictate long-term fundamental performance.
⚠ Risk flags
- Substantial equity dilution across existing shareholders
- Details of the underlying swapped asset/business not covered in this disclosure
Key Highlights
Promoter allotted 4,95,000 equity shares via preferential allotment under a share swap
Absolute holding increased from 7,00,000 shares to 11,95,000 shares
Percentage stake decreased from 8.32% to 4.86% due to total equity base expansion
Total share capital expanded nearly threefold from 84,08,972 shares to 2,45,91,772 shares (Rs 24.59 Cr)
👀 What to Watch
Monitor upcoming filings detailing what assets or entities were acquired via the share swap that expanded the total equity base by nearly 192%.
iSERA Lifesciences Allots 1.62 Cr Shares at Rs 48.20 in 1:1 Share Swap Deal
iSERA Lifesciences Limited has approved the allotment of 1,61,82,800 equity shares of face value Rs 10 each at an issue price of Rs 48.20 per share (including Rs 38.20 share premium). The total transaction value stands at approximately Rs 78 Cr, which dwarfs the company's TTM revenue of Rs 16 Cr and net worth of Rs 8 Cr. The allotment is executed via a 1:1 share swap with shareholders of iSERA Biological Limited. The issue covers 196 allottees spanning promoters, promoter groups, and marquee non-promoter individuals.
Confidence: HIGH
What changedThe board finalized the allotment of 1.62 crore equity shares to acquire shares of iSERA Biological Limited under a 1:1 swap arrangement.
Why it mattersThe Rs 78 Cr swap transaction substantially expands the equity base and transforms the scale and operating profile of the company relative to its existing Rs 16 Cr revenue base.
Shares allotted: 1,61,82,800Issue price per share: Rs. 48.20Swap ratio: 1:1Number of allottees: 196Implied transaction value: ~Rs 78 Cr
📅 Short termMarket attention will focus on equity dilution impact and the formal listing and trading clearance of the newly allotted shares on BSE.
📈 Long termStructural transformation of the business through the reverse or direct operational consolidation of iSERA Biological Limited into the listed entity.
⚠ Risk flags
- Significant equity dilution
- Lack of detailed financial disclosures on iSERA Biological Limited in this filing
- Valuation premium compared to historical net worth base
Key Highlights
Allotment of 1,61,82,800 fully paid-up equity shares approved on October 01, 2026
Issued at Rs 48.20 per share (Rs 10 face value plus Rs 38.20 premium)
Executed via a 1:1 share swap ratio for equity shares of iSERA Biological Limited
Transaction covers 196 allottees including promoter and non-promoter categories
👀 What to Watch
Track the upcoming corporate filing on final shareholding patterns, trading approvals from BSE for the newly allotted shares, and financial integration details of iSERA Biological Limited.
iSERA Lifesciences Allots 1.62 Cr Shares at Rs 48.20 in 1:1 Share Swap Deal
iSERA Lifesciences Limited has approved the allotment of 1,61,82,800 equity shares of face value Rs 10 each at an issue price of Rs 48.20 per share (including Rs 38.20 share premium). The total transaction value stands at approximately Rs 78 Cr, which dwarfs the company's TTM revenue of Rs 16 Cr and net worth of Rs 8 Cr. The allotment is executed via a 1:1 share swap with shareholders of iSERA Biological Limited. The issue covers 196 allottees spanning promoters, promoter groups, and marquee non-promoter individuals.
Confidence: HIGH
What changedThe board finalized the allotment of 1.62 crore equity shares to acquire shares of iSERA Biological Limited under a 1:1 swap arrangement.
Why it mattersThe Rs 78 Cr swap transaction substantially expands the equity base and transforms the scale and operating profile of the company relative to its existing Rs 16 Cr revenue base.
Shares allotted: 1,61,82,800Issue price per share: Rs. 48.20Swap ratio: 1:1Number of allottees: 196Implied transaction value: ~Rs 78 Cr
📅 Short termMarket attention will focus on equity dilution impact and the formal listing and trading clearance of the newly allotted shares on BSE.
📈 Long termStructural transformation of the business through the reverse or direct operational consolidation of iSERA Biological Limited into the listed entity.
⚠ Risk flags
- Significant equity dilution
- Lack of detailed financial disclosures on iSERA Biological Limited in this filing
- Valuation premium compared to historical net worth base
Key Highlights
Allotment of 1,61,82,800 fully paid-up equity shares approved on October 01, 2026
Issued at Rs 48.20 per share (Rs 10 face value plus Rs 38.20 premium)
Executed via a 1:1 share swap ratio for equity shares of iSERA Biological Limited
Transaction covers 196 allottees including promoter and non-promoter categories
👀 What to Watch
Track the upcoming corporate filing on final shareholding patterns, trading approvals from BSE for the newly allotted shares, and financial integration details of iSERA Biological Limited.
iSERA Lifesciences Reports Rs 33.62 Lakh Net Loss on Zero Revenue for Q1 FY27
iSERA Lifesciences reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 1.16 crore in the preceding quarter. The company posted a net loss of Rs 33.62 lakh, compared to a profit of Rs 54.98 lakh in Q4 FY26 and a loss of Rs 1.54 lakh in the same quarter last year. Total expenses for the quarter were Rs 33.62 lakh, almost entirely driven by 'Other Expenses' of Rs 31.31 lakh. The company's reserves remain negative at Rs -49.81 lakh, highlighting continued financial instability.
Confidence: HIGH
What changedThe company has swung from a profitable quarter with revenue (Q4 FY26) back to a zero-revenue, loss-making position in Q1 FY27.
Why it mattersZero revenue indicates a total halt in business operations for the period, which is critical given the company's existing debt of Rs 11 crore and negative reserves.
Revenue from Operations (Q1 FY27): Rs 0Net Loss (Q1 FY27): Rs 33.62 lakhTotal Expenses: Rs 33.62 lakhReserves and Surplus: Rs -49.81 lakhEPS (Basic): Rs -1.60
📅 Short termThe stock is likely to face downward pressure due to the lack of revenue and widening losses compared to the previous year.
📈 Long termThe long-term outlook remains highly uncertain as the company struggles with inconsistent revenue and a weak balance sheet with negative reserves.
⚠ Risk flags
- Zero operational revenue
- Negative reserves
- High debt-to-equity ratio (22.17)
- Significant volatility in quarterly performance
Key Highlights
Revenue from operations dropped to Rs 0 in Q1 FY27 from Rs 1.16 crore in the previous quarter.
Net loss widened significantly to Rs 33.62 lakh from a loss of Rs 1.54 lakh in Q1 FY26.
Other expenses accounted for 93% of total quarterly expenditure at Rs 31.31 lakh.
Negative reserves increased to Rs -49.81 lakh as of June 30, 2026.
Paid-up equity share capital remains constant at Rs 840.90 lakh.
👀 What to Watch
Investors should monitor if the company can resume revenue generation in subsequent quarters and investigate the nature of the 'Other Expenses' that led to the current loss.
iSERA Lifesciences Reports Q1 FY27 Net Loss of ₹33.62 Lakhs on Zero Operating Revenue
iSERA Lifesciences (formerly Covidh Technologies) reported a sharp decline in performance for Q1 FY27, with operating revenue dropping to zero from ₹1.16 Cr in the previous quarter. The company posted a net loss of ₹33.62 Lakhs, compared to a profit of ₹54.88 Lakhs in Q4 FY26. Total expenses for the quarter were ₹39.39 Lakhs, largely driven by 'Other Expenses' of ₹37.08 Lakhs. The company continues to struggle with negative reserves, which widened to ₹43.81 Lakhs.
Confidence: HIGH
What changedThe company transitioned from a profitable quarter with active revenue to a loss-making quarter with zero operating revenue.
Why it mattersFor a company with a TTM revenue of only ₹16 Cr and a history of zero net worth, a quarter with no revenue and widening losses significantly increases liquidity and solvency risks.
Revenue from Operations: ₹0.00Net Loss (Q1 FY27): ₹33.62 LakhsOther Expenses: ₹37.08 LakhsEPS (Basic): ₹-1.60Paid-up Equity Capital: ₹8.41 Cr
📅 Short termThe stock is likely to face downward pressure as the market reacts to the lack of operating revenue and the return to a loss-making position.
📈 Long termThe long-term outlook remains highly uncertain given the company's negative reserves, high debt-to-equity ratio (22.17), and inconsistent revenue streams.
⚠ Risk flags
- Zero operating revenue for the current quarter
- Negative reserves of ₹43.81 Lakhs
- High debt-to-equity ratio of 22.17
- Significant volatility in promoter holding in recent periods
Key Highlights
Revenue from operations fell to ₹0.00 for the quarter ended June 30, 2026, compared to ₹1.16 Cr in the preceding quarter.
Net loss stood at ₹33.62 Lakhs for Q1 FY27, a reversal from the ₹54.88 Lakhs profit recorded in Q4 FY26.
Other Expenses accounted for ₹37.08 Lakhs, representing over 94% of the total quarterly expenditure.
Negative reserves (excluding revaluation) increased to ₹43.81 Lakhs from ₹16.19 Lakhs in the previous quarter.
Basic and Diluted EPS for the quarter was negative ₹1.60.
👀 What to Watch
Investors should monitor the company's ability to resume revenue generation in its IT/ITES segment and watch for any management commentary regarding the sudden cessation of operations this quarter.
